This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Kyungpook National University Industry-Academic Cooperation Foundation. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Ji Min Moon: Innovator in Therapeutic Agents for Infectious Diseases
Introduction
Ji Min Moon is a prominent inventor based in Daegu, South Korea. He has made significant contributions to the field of medicinal chemistry, particularly in developing therapeutic agents for infectious diseases. His innovative work focuses on addressing vascular inflammation associated with HMGB1 protein activity.
Latest Patents
Ji Min Moon holds a patent for a polysubstituted imidazolo[4,5-c][1,2]thiazine derivative. This invention is particularly noteworthy as it relates to an agent that can be used to treat infectious diseases linked to vascular inflammation. The patent highlights the effectiveness of this derivative in increasing the survival rate in sepsis, as demonstrated through CLP-induced sepsis animal experiments. The agent, which may include a pharmaceutically acceptable salt, shows promise as a therapeutic solution for various infectious and vascular inflammatory diseases.
Career Highlights
Ji Min Moon is affiliated with the Kyungpook National University Industry-Academic Cooperation Foundation. His role at this institution allows him to engage in cutting-edge research and development, contributing to advancements in medical science. His work is characterized by a commitment to improving health outcomes through innovative therapeutic solutions.
Collaborations
Ji Min Moon collaborates with notable colleagues, including Taeho Lee and Sangkyu Lee. These partnerships enhance the research efforts and broaden the impact of their collective work in the field of medicinal chemistry.
Conclusion
Ji Min Moon's contributions to the development of therapeutic agents for infectious diseases underscore his role as an influential inventor. His patented work on polysubstituted imidazolo[4,5-c][1,2]thiazine derivatives represents a significant advancement in the fight against vascular inflammation and related health challenges.